Date: {{$ActivityAssignDate}}

Dear Dr. {{ $doctorName }},

Subject: A survey among dermatologists to understand usage pattern of low-dose micronized-isotretinoin in severe recalcitrant nodular acne in India

Acne vulgaris, or acne, is the most common skin condition, affecting approximately 80 to 90 percent of adolescents and 40 to 60 percent of adults. Up to 50 million Americans (~15%) suffer from acne each year regardless of sex, skin color, or ethnicity. Severe acne can cause considerable physical scarring and psychological damage and warrants appropriate treatment.

Severe acne often requires systemic treatment. Oral isotretinoin is an effective systemic therapy for the treatment of severe acne, hormonal acne, and recalcitrant acne. Conventional isotretinoin use has challenges and limitations that have been addressed by newer formulations. This review compares currently approved and available isotretinoin formulations for acne treatment with a focus on how newer formulations simplify dosing regimens, improve bioavailability, and enhance clinical outcomes in patients with severe, recalcitrant, nodular acne. This will provide clinicians with practical information for both patient education and optimizing treatment outcomes

This survey is conducted among dermatologists to understand usage pattern of low-dose micronized-isotretinoin in severe recalcitrant nodular acne in India.

As you will be spending some extra time to give your feedback on the questionnaire based on your clinical experience, we offer to pay you by cheque a professional fee of Rs {{$contractAmount}}, on receiving the completed Survey Questionnaire Form from you.

We trust you and we are partners in promoting safe and effective drug therapy. In that spirit we hope you will consent to participate in this study. If you do, please sign and return the enclosed reply along with your visiting card for accuracy of records.